Abstract:Purpose of the review: Acid suppression with proton pump inhibitors (PPIs) represents the standard of care in the treatment of acid-related diseases. However, despite their effectiveness, PPIs display some intrinsic limitations, which underlie the unmet clinical needs that have been identified over the past decades. The aims of this review are to summarize the current status and future development of the new class of antisecretory drugs (potassium-competitive acid blockers, P-CABs) that have recently been introduced into medical practice. Recent findings: Over the past decades, clinical needs unmet by the current acid suppressants have been recognized, especially in the management of patients with GERD, Helicobacter pylori infection and NSAID-related peptic ulcer. The failure to address these needs is mainly due to their inability to achieve a consistent acid suppression in all patients and, particularly, to control nighttime acidity. It was then realized that an extended duration of acid suppression would exert additional benefits. The available data with P-CABs show that they are able to address these unmet clinical needs. Four different P-CABs (vonoprazan, tegoprazan, fexuprazan and keverprazan) are currently available. However, only two of them are approved outside Asia. Vonoprazan is available in North, Central and South America while tegoprazan is marketed only in Latin American countries. Two other compounds (namely linazapran glurate and zestaprazan) are presently under clinical development. While clinical trials on GERD have been performed with all P-CABs, only vonoprazan and tegoprazan have been investigated as components of Helicobacter pylori eradication regimens. The available data show that-in the above two clinical indications-P-CABs provide similar or better efficacy in comparison with PPIs. Their safety in the short-term overlaps that of PPIs, but data from long-term treatment are needed.

H+/K+-ATPase inhibitors: a patent review.

Pump Proton and Laryngeal H<SUP>+</SUP>/K<SUP>+</SUP> ATPases

Discovery of novel benzimidazole derivatives as potent potassium-competitive acid blockers for the treatment of acid-related diseases

Inhibiting the proton pump: mechanisms, benefits, harms, and questions

A Patent Review of Aldosterone Synthase Inhibitors (2014-Present)

Potassium-competitive acid blockers - are they the next generation of proton pump inhibitors?

Protonated Form: the Potent Form of Potassium-Competitive Acid Blockers.

Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases

Potassium-competitive Acid Blockers: Current Clinical Use and Future Developments

KFP-H008 Blocks Gastric Acid Secretion Through Inhibiting H+-K+-ATPase.

Potassium-competitive acid blockers and acid-related disorders

Kinesin Spindle Protein Inhibitors in Cancer: a Patent Review (2008 – Present)

Design, Synthesis and Biological Evaluation of Novel 5-Methyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole Derivatives As Potent Potassium-Competitive Acid Blockers.

Potassium Competitive Acid Blockers: A New Paradigm For The Management of Stomach Acid Disorders

Gastric Adenosine Triphosphatases: A Review of Their Possible Role in HCL Secretion

Cathepsin B and L Inhibitors: a Patent Review (2010 - Present).

Review article: potassium‐competitive acid blockers for the treatment of acid‐related disorders

Human F-ATP synthase as a drug target

Cancer-ATPases as a New Strategy against + Targeting Vacuolar H Updated

Role of Acid Suppression in Acid-related Diseases: Proton Pump Inhibitor and Potassium-competitive Acid Blocker

Computational Insights into the Interaction Mechanism of Triazolyl Substituted Tetrahydrobenzofuran Derivatives with H + ,K + -Atpase at Different Ph